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Delivery of erythropoietin by encapsulated myoblasts in a ge- transfusions. Treatment entails regular injection of Epo,
netic model of severe anemia. 2 to 4 times per week, given either intravenously or subcu-
Background. Existing animal models of anemia inadequately taneously [1].reflect the hematocrit usually present in chronic renal failure
Gene transfer techniques simplify protein-based Epo(CRF) patients and do not permit long-term treatment studies.
therapies, as required molecules can be produced in situ,The transgenic mouse strain 134.3LC (Epo-TAgH) displays a
severe chronic anemia resembling that observed clinically dur- eliminating dependence on exogenous injections and fa-
ing CRF, while displaying an active, normal life span. This cilitating the delivery of Epo to anemic patients. Methods
phenotype makes it a particularly interesting mouse model for include direct injection of viral or plasmid vectors express-testing erythropoietin (Epo)-based gene transfer strategies.
ing the Epo transgene [2–4] and the transplantation ofMethods. Ex vivo gene therapy was employed to administer
cells or tissue genetically engineered to secrete Epo [5].mouse Epo to homozygous anemic Epo-TAgH mice. Encapsu-
lated C2C12 myoblasts genetically engineered to secrete 163 IU Using these gene therapy strategies, Epo may be pro-
mouse Epo/106 cells/day were subcutaneously transplanted on duced in a continuous fashion and thereby replace the
the dorsal flank of the mice. Efficacy of delivered Epo was
function of damaged endogenous Epo-secreting cells inmonitored by weekly measurements of animal hematocrit.
the diseased kidney [2–5]. Anemic chronic renal failureResults. Most treated homozygous Epo-TAgH mice displayed
only a transient rise in hematocrit before eventually decreasing (CRF) patients treated using gene therapy approaches
to levels as low as 3%. Administering the immunosuppressor will benefit from stable low levels of endogenously pro-
anti-CD4 monoclonal antibody (mAb) to homozygous Epo- duced Epo, which may raise their hematocrit to normal
TAgH mice, beginning at the time of implantation, permitted
levels as opposed to Epo injections that maintain patientsa rise in hematocrit that remained stable at elevated levels in
at slightly depressed hematocrits.cases of continued immunosuppression.
Conclusions. Mice having the T antigen insertion in both Animal models have been developed using a partial
Epo alleles appeared to develop an immune response to the nephrectomy procedure to reproduce conditions that lead
natural mouse Epo delivered by encapsulated cells. By pre- to anemia in patients with CRF. These models suffer fromventing this reaction using immunosuppression, we demonstrate
shortcomings, including hematocrits that do not decreasethat encapsulated myoblasts can deliver therapeutic doses of
to the levels observed in CRF and systemic toxicity duemouse Epo systemically and restore hemopoiesis in a genetic
model of severe anemia. to renal failure, which leads to animal death [6].
The transgenic mouse strain (134.3 LC, Epo-TAgH),
which has a stable chronic anemia due to a relative defi-
In situations of chronic renal failure, patients develop ciency of erythropoietin, may prove to be a valuable tool
anemia due to inadequate erythropoietin (Epo) produc- for refining gene transfer approaches for delivery of Epo
tion by the kidney. Recombinant Epo, administered as a [7]. Mice homozygous for the modified Epo allele are
replacement therapy, restores hematocrit and blood he- severely anemic, with hematocrits ranging from 13% to
moglobin concentration, eliminating the need for blood 20% [7, 8], but otherwise appear healthy and remain
active. These mice display hematocrit levels comparable
to those observed in patients with chronic renal failure,Key words: transplantation, immunosuppression, encapsulation, ane-
mia, chronic renal failure, hematocrit, gene therapy, hemopoiesis. making them an interesting model for the study of Epo-
based gene therapies.Received for publication September 27, 2001
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to these anemic mice. With this method, cells are en- MD, USA) were transfected with the pPI-mEpo-ND
plasmid [5] using calcium phosphate precipitation (mam-closed inside a semipermeable polymer membrane, which
isolates encapsulated cells and prevents direct cell-to- malian transfection kit; Stratagene, Basel, Switzerland).
C2C12 mEpo myoblasts were resuspended at 1105 cells/cell contact with the host, thereby eliminating antigen
recognition and immune rejection through direct presen- L and then injected into semipermeable polyethersul-
fone (PES) hollow fibers (OD 720 m; ID 524 m; mo-tation. Capsule geometry facilitates device implantation
and retrieval. Genetically-modified allogeneic cell lines lecular weight cutoff 280 kD; Akzo Nobel Faser AG,
Wupperthal, Germany) as previously described [9]. One-are attractive for this purpose as they can be screened
for biosafety and banked in liquid nitrogen, permitting centimeter long capsules lacking matrix were loaded with
C2C12 mEpo myoblasts at a density ranging from 2  105a standardized therapy that uses a universal donor cell.
The aim of the present study was to evaluate the Epo- to 6  105 cells per capsule. Encapsulated cells were
maintained in culture at least three days prior to implan-TAgH mouse strain as an anemic animal model resem-
bling human CRF for testing encapsulated cell-based tation.
Epo delivery. For treatment, an allogeneic C2C12 myoblast
Measurement of Epo secretioncell line engineered to secrete 163 IU Epo/106cells/day
was encapsulated and implanted subcutaneously on the Mouse Epo (mEpo) secretion from encapsulated myo-
blasts was measured at pre-implant and post-explant bydorsal flank of Epo-TAgH mice.
incubating capsules for one hour in 1 mL of medium. Epo
levels in the conditioned media were measured using an
METHODS
enzyme-linked immunosorbent assay (ELISA; Quanti-
Epo-TAgH mouse line kine IVD; R&D Systems, Minneapolis, MN, USA) with
a detection limit of 2.5 mIU hEpo/mL. Cross-reactionThe transgenic mouse strain employed for these stud-
ies was the product of the homologous recombination of the kit allowed measurement of mEpo in culture super-
natants [5]. The detection limit of mEpo released by en-within the Epo gene, resulting in a modified Epo gene
(Epo-TAgH) containing a 2.7 kb fragment coding for the capsulated cells was approximately 250 mIU mEpo/day.
entire SV40 large T antigen inserted in the 5 untranslated
Capsule implantationregion upstream the ATG site [www.mgu.har.mrc.ac.uk/
fesa/fesa.html; TgH(eposvT)1Pjr] [7]. Animal experimen- Animals were anesthetized by inhalation of isoflurane
(Forene; Abbott Laboratories, Cham, Switzerland) andtation was conducted following the review and approval
by the Swiss Cantonal Vetinarian Services. Wild-type, capsules were then implanted subcutaneously in the dor-
sal flank using a trocar (Abbocath-T 16 G; Abbott Labo-heterozygous and homozygous mice were differentiated
from one another by polymerase chain reaction (PCR) ratories) [9]. Upon recovery, the animals were returned
to the animal care facility, where they had access to foodof genomic DNA. The forward primer 5-ATGG
ATAAAGTTTTAAACAGAGAGG-3, lying in the 3 and water ad libitum.
region of the inserted SV40 large T antigen, and the
Western blot analysisreverse primer 5-GGAGGTCACAGGTCCTTAGCC
TGTG-3, present in the first intron of murine erythro- Cells and tissue were lysed in a RIPA buffer containing
1% Triton X-100, 0.15 mol/L NaCl, 10 mmol/L Tris (pHpoietin gene, were used to identify the inserted SV40 T
antigen sequence. 7.4), 50 g/mL phenylmethylsulfonyl fluoride (PMSF)
and 2 g/mL aprotinin at 4C for 30 minutes. Immuno-
RT-PCR of the murine Epo cDNA precipitation was performed on 1 mg of total protein in
1 mL of radioimmunoprecipitation assay (RIPA) bufferMice were placed in a hypoxic environment containing
7% oxygen for 24 hours as described previously [9]. containing 1 g TAG antibody (AB-1 monoclonal; On-
cogene Research, Darmstadt, Germany) or 1 g anti-Thereafter, total RNA was extracted from kidney tissue
using the Trizol reagent (Life Technologies, Paisley, UK) human Epo (polyclonal; R&D Systems) overnight at
4C. The AB-1 monoclonal antibody (mAb) is specificand the murine Epo cDNA was amplified from cDNA
prepared from isolated RNA by PCR using the mEpo for the first exon of the SV40 T antigen. The anti-human
Epo Ab also is employed in the ELISA kits that cross-forward primer: 5-ATGGGGGTGCCCGAACGTCC
CACCC-3, containing regions in the first and second react with mouse Epo. To this mixture 20 L protein-
A Sepharose (Pharmacia, Duebendorf, Switzerland) wasexons, and the mEpo reverse primer: 5-TCACCTGTC
CCCTCTCCTGCAGACC-3. added, followed by a one-hour incubation at 4C and a
wash (4) in RIPA buffer. Protein precipitates were
Cell culture and cell encapsulation migrated on a 10% gel and transferred to a nitrocellulose
filter. A rabbit polyclonal anti-SV40 T antigen antibodyMouse C2C12 myoblasts obtained from the American
Type Culture Collection (CRL 1772; ATCC, Rockville, (R613) diluted 1/2000 (a kind gift of Dr. S. Efrat, Albert
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Fig. 1. (A) Transgenic construct employed
for generating the 134.3 LC, Epo-TAgH mouse
line. Epo in the untranslated region is in the
gray bars and in the translated region is solid
black; the large T antigen is represented by
the hatched area; Ex is exon. (B ) Western
blot of the immunoprecipitated SV40 large
T antigen and Epo expressed in kidneys of
anemic homozygous Epo-TAgH mice (/)
and wild-type (/) littermates. Kidney pro-
tein extracts were immunoprecipitated either
with antibodies against the SV40 large T anti-
gen or Epo. Cell lysates of bTC-tet cells ex-
pressing the SV40 large T antigen were em-
ployed as a positive control (hc is heavy chain)
[10]. (C ) rtPCR of mouse Epo expressed in
the kidney tissue of homozygous (/) and
heterozygous (/) Epo-TAgH mice. The
band migrating near 600 bp corresponds to
the size of the mouse Epo cDNA. Reactions
carried out in the absence of primers served
as negative controls: (/) control and (/)
control lanes.
Einstein College of Medicine, NY, USA) was employed zygous for the Epo-TAgH insertion were severely anemic
to label the transferred SV40 large T antigen. compared to heterozygotes (P  0.001), having hemato-
crit values of 19.2 	 0.2% (N 
 147).
Immunosuppression with anti-CD4 mAb Western blot analysis of kidney extracts in homozy-
gous Epo-TAgH mice revealed the presence of theThe anti-mouse CD4 mAb, a depleting anti-mouse
SV40 T antigen as a doublet, with the upper band corre-CD4 mAb, was purified from conditioned media used
sponding to the expected size (80 kD) of the large Tto culture the rat GK1.5 hybridoma (ATCC). The mAb
antigen (Fig. 1B). The lower band was believed to resultwas resuspended in 0.1 mol/L glycine (pH 7.0) and sterile
from variations in protein phosphorylation. No signalfiltered for injection. Animals were administered 0.25
was detected on Western blot analysis with anti-T anti-mg mAb per intraperitoneal injection either on days3,
gen Ab when kidney extracts were first immunoprecipi-0, 3 or on days 3, 0, 3, 14, 28, 42 relative to
tated using an anti-Epo Ab. This suggests that the Tcapsule implantation.
antigen and Epo are not produced as a fusion protein.
Statistical analysis The presence of a full-length mEpo messenger RNA in
homozygous Epo-TAgH mice was verified using rtPCRData are expressed as mean 	 SEM. The data ob-
(Fig. 1C), indicating that there is transcription beyondtained for the different animal groups were analyzed
the SV40 T antigen polyadenylation site. Epo was notfor statistical significance using analysis of variance
detected in the serum of homozygous Epo-TAgH mice(ANOVA) followed by a Fischer’s post hoc test. A P 
either by Western analysis or ELISA techniques, con-0.05 was considered to be statistically significant.
firming that the endogenous Epo levels were extremely
low.
RESULTS
Response of Epo-TAgH mice to mEpo delivered byCharacterization of the transgenic Epo-TAgH anemic
encapsulated cellsmouse line
To correct the severe anemia in the homozygous Epo-The Epo-TAgH mouse line was generated by the ho-
TAgH mice, animals were implanted subcutaneouslymologous recombination of the Epo-TAgH transgene
with encapsulated C2C12 myoblasts engineered to secrete(Fig. 1) at the locus of the endogenous Epo gene [7]. Mice
mouse Epo. Wild-type littermates were implanted withhaving one copy of this Epo-TAgH allele were slightly
identical devices for comparison purposes. Within oneanemic with a significantly (P  0.001) lower hematocrit
week, both animal groups responded to the implants byvalue (36.1 	 0.4%, N 
 86) than the wild-type back-
ground strain (41.2 	 0.4%, N 
 56). Those mice homo- increasing their hematocrit levels (Fig. 2).
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cells were observed inside the explanted capsules, se-
creted Epo levels by the devices were below the 250
mIU/day detection level of the ELISA kit. This suggests
that only very low levels of continuously released Epo
were required to normalize anemic mice.
Immunosuppression of treated homozygous
Epo-TAgH mice
Further studies were pursued to verify whether the
decreases in hematocrit observed in homozygous mice
were related to an immune reaction to foreign Epo. The
physiological response of homozygous Epo-TAgH mice
to mouse Epo delivered by encapsulated myoblasts was
evaluated in a context where recipients were immuno-
Fig. 2. Comparison of wild-type (/; ) and anemic homozygous suppressed. Mice were given a specific anti-CD4 mAb
(/; ) Epo-TAgH mice to subcutaneously implanted capsules secre-
for depletion of CD4 T cells.ting mouse Epo (N 
 7). Data are presented as mean 	 SEM (*P 
Homozygous Epo-TAgH mice were treated with anti-0.05; **P  0.01).
CD4 mAb either transiently, on days (3, 0, 3) or
in a repeated manner on days (3, 0, 3, 14, 28,
42) relative to the moment of capsule implantation.
At four weeks the homozygous mice began to show Mice receiving transient depletion of CD4 T cells be-
a significant decline in their hematocrit as compared to came polycythemic, with hematocrits rising to 80% (Fig.
wild-type mice. Differences in blood hematocrit in- 4A). During the period from weeks six to eight, two out
creased with time, and by week eight, the wild-type group of the five animals began to decrease their hematocrits
had stabilized at 78% with homozygous mice decreasing (Fig. 4A), suggesting that transient immunosuppression
to an average of 30%. Capsules were explanted on week was insufficient. At explant, all capsules secreted measur-
eight and analyzed for secretion of Epo. Devices re- able levels of mEpo (Table 1). Homozygous Epo-TAgH
trieved from wild-type mice displayed on average a two- mice repeatedly administered anti-CD4 mAb every 14
fold higher Epo secretion than those explanted from days following implantation increased their hematocrit
homozygous mice. The ratio of Epo released at explant levels and maintained an average near to 80% for the
versus implant was employed to measure relative cell eight weeks investigated (Fig. 4B). Explanted capsules
survival within the devices (Table 1). Despite the diver- continued to produce mEpo at a slightly higher level,
gence in the hematocrit of the two groups, no statistically although not significantly, than those retrieved from mice
significant difference was observed in the relative capsule transiently treated with anti-CD4 mAb (Table 1). His-
secretion explant/implant ratio. In separate experiments tology of recovered capsules contained viable clusters of
lasting longer than eight weeks, implanted homozygous myoblasts dispersed within implants, with a characteris-
Epo-TAgH mice became critically anemic compared to tic necrosis at the center of the capsule (Fig. 5).
baseline levels (19.2%), with hematocrits dropping to as
low as 3% (data not shown). This suggested that homozy-
DISCUSSIONgous mice develop an immune response to the delivered
natural mouse Epo that may cross-react with the endoge- The aim of the present report was to explore the effi-
nous Epo of the Epo-TAgH strain. On the contrary, het- cacy of Epo delivery by encapsulated engineered my-
erozygous mice never became anemic or showed any oblasts in an animal model of severe anemia that most
indication of an Epo-derived immune response following accurately reflects the blood hematocrit levels found in
implantation of capsules releasing mouse Epo (data not CRF patients. Previously, it was observed that Epo ad-
shown). This was expected, as heterozygous mice still ministered using cell encapsulation was able to induce
have one remaining copy of the unaltered Epo gene. polycythemia in healthy mice [5]. Bearing in mind the
There were rare exceptions to this observation, proba- eventual clinical application of this technology, it is nec-
bly due to heterogeneity in the immune response. Nota- essary to demonstrate that encapsulated Epo delivery
bly, two implanted homozygous Epo-TAgH mice main- can restore hemopoiesis in situations of chronic anemia.
tained elevated hematocrits for periods of 9 and 12 months To date, most Epo-based gene therapies have been
(Fig. 3). Following removal of the capsules, animal hema- conducted in healthy animals, which respond to deliv-
tocrit returned to pre-implant levels, demonstrating that ered Epo by becoming polycythemic with hematocrits
the encapsulated myoblasts were responsible for the ranging from 70% to 90%. To reproduce the conditions
leading to anemia in patients with chronic renal failure,long-term correction of anemia. While clusters of viable
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Table 1. Capsule Epo secretion at implant versus explant in Epo-TAgH mice
Mouse Epo secretion IU/day
Animal groups Implant Explant Expl/Impl %
Homozygous (/) (N 
 7) 4.96	0.42 1.11	0.14 22.4
Wild-type (/) (N 
 7) 6.13	0.67 2.21	0.57 36.1
Immunosuppressed homozygous (/) mice
Anti-CD4 mAb (days 3, 0, 3) (N 
 5) 11.0	1.7 1.4	0.4 12.7
Anti-CD4 mAb (days 3, 0, 3, 14, 28, 42) (N 
 5) 9.4	1.9 1.8	0.5 19.1
Data are presented as average 	 SEM.
Fig. 3. Two of the homozygous mice maintaining elevated hematocrits
were followed for a period of 9 and 12 months prior to explantation
(arrows), at which point they returned to their normal baseline hemato-
crit levels. Symbols are: () mEPO; () control.
partially nephrectomized animals have been employed
as a model for anemia. One study has been described in
which an ex vivo gene therapy approach was effective
in treating anemia in partially nephrectomized nude mice
[6]. Unfortunately, the partial nephrectomy model is
complicated as systemic toxicity due to renal insuffi-
ciency eventually leads to animal death, prohibiting long-
term follow up subsequent to Epo gene delivery [6].
Hematocrits of nephrectomized animals lie near 34%,
which is significantly higher than most cases of CRF
observed clinically.
Fig. 4. Homozygous anemic Epo-TAgH mice implanted with capsulesOn the other hand, mice homozygous for the Epo- secreting mouse Epo were treated with anti-CD4 mAb. Efficacy of
TAgH insertion naturally have hematocrits near 20%, (A ) transient (days 3, 0, 3) or (B ) intermittent dosing (days 3, 0,
3, 14, 28, 42) was compared.while leading a normal life span, making this strain clini-
cally relevant for evaluating Epo gene transfer tech-
niques. The response of the background, wild-type Epo-
TAgH mice to mouse Epo delivered by encapsulated In certain circumstances, it has been observed that pro-
myoblasts resembled that previously observed in C3H, tein replacement therapy may lead to the development
DBA/2J, and C57/Bl6 mice strains [5], with animals in- of host neutralizing antibodies against the therapeutic
creasing their hematocrit and maintaining elevated levels product. This includes the case where there are species
throughout the study period. Unexpectedly, treated ho- incompatibilities between delivered and endogenous
mozygous Epo-TAgH mice displayed only a transient proteins [11]. In other situations, a host may be incapable
rise in hematocrit before eventually becoming acutely of naturally producing a protein, such as factor IX, and
anemic. This was not a result of insufficient Epo delivery, hence develop antibodies against “foreign” recombinant
as explanted devices continued to release protein levels factor IX given as a therapy [12].
Homozygous Epo-TAgH mice produce undetectablecomparable to capsules retrieved from wild-type mice.
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While it is not our intent that systemic immunosup-
pression be used as a support therapy for Epo delivery by
encapsulated cells, it was necessary to immunosuppress
homozygous anemic Epo-TAgH mice in order to follow
the blood hematocrit response to administered Epo in
the absence of an interfering antibody reaction. The
doses of Epo required from encapsulated cells to correct
anemic mice to normal hematocrit levels (45%) appears
to be below 250 mIU/day, as these levels led to polycythe-
mia (80%) in anti-CD4 mAb treated mice. This sug-
gests that perhaps as little as 10 to 50 mIU/day would
be needed to treat these anemic mice.
In a few isolated cases, a long-term correction of ane-
mia was observed in homozygous Epo-TAgH mice in
the absence of immunosuppression. As this was a rare
phenomenon, it is likely due to the natural heterogeneity
in a host’s immune response to Epo. The capsule removed
from the mouse with a hematocrit range from 40% to
60% secreted Epo levels below the 250 mIU/day detec-
tion limit, as might be predicted. Nevertheless, capsules
containing Epo secreting cells restored hemopoiesis in
anemic animals for periods as long as 12 months, validat-
Fig. 5. Photomicrograph of encapsulated C2C12 mEpo myoblasts fol- ing this technology for use in prolonged therapies.lowing 8 weeks in vivo. Clusters of viable myoblasts were observed
In the clinic, CRF patients are treated with bolus doseswithin the capsule’s interior.
ranging from 1500 to 4000 IU Epo administered three
times a week. Based on these values, we estimate that
to restore hematocrit to acceptable levels, CRF patients
levels of mouse Epo due to the insertion of the large T will require capsules continuously delivering doses of at
antigen. Based on the effects of immunosuppression on least 100 IU Epo per day. The positive effects of encapsu-
animal reaction to Epo, it is believed that homozygous lated Epo delivery in the anemic model have motivated
Epo-TAgH mice develop an immune response to exoge- us to scale up our system for human application. At pres-
nously delivered mouse Epo. This is reinforced by the ent, we are in the pre-clinical phase of evaluating non-
findings that a continued therapy using anti-CD4mAb tumorigenic human allogeneic cells that can secrete up to
was more effective than transient dosing regimens in 1000 IU human Epo per day. We believe that these levels
maintaining elevated hematocrit levels. Treatment with of production will allow us to show this first efficacy of
anti-CD4mAb has been demonstrated to be one of the an ex vivo Epo gene therapy in CRF patients.
most efficacious means of preventing the development
of neutralizing antibodies against a recombinant gene ACKNOWLEDGMENTS
product in vivo [11].
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